Dr. Hachigian is a co-founder and vice president, strategy and operations at Be Biopharma. Prior to joining Be Bio, she was a principal at Longwood Fund where she co-founded ImmuneID (founding CEO and current director), TScan Therapeutics (founding president and director) and Immunitas Therapeutics (founding president and director). Lea has driven all aspects of company creation, including private financings, scientific strategy, business development, team building and early operations. Together, companies she has co-founded at Longwood Fund have raised over $250 million in venture financing and entered collaborations with leading industry partners. Additionally, Lea served as a member of the Longwood Fund investment team, leading diligence and deal efforts across all areas of early-stage platform and therapeutics companies.
Lea received her Ph.D. from MIT in molecular and cellular neuroscience where she was a NSF Graduate Research Fellow. As a graduate student in the Heiman Lab at the Broad Institute, she studied the determinants of neuronal identity and vulnerability in disease. Prior to her doctorate, Lea received an A.B. from Harvard University where she graduated magna cum laude with highest honors in neurobiology and received a certificate in mind brain and behavior. While at Harvard, Lea researched genetic models of developmental disorders in the Fagiolini/Hensch lab at Children's Hospital/Harvard Medical School. She has received numerous fellowships for her research and multiple teaching awards for her work with both undergraduate and graduate students. Lea was named to the Forbes 30 Under 30 list for healthcare for her work as a co-founder of TScan Therapeutics.
